Twist Bioscience (TWST) Net Cash Flow (2017 - 2026)

Twist Bioscience (TWST) has reported Net Cash Flow for 10 consecutive years, with -$5.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 40.97% year-over-year to -$5.3 million in Q2 2026; TTM through Jun 2026 was -$84.5 million, a 121.33% decrease from a year earlier, with the FY2025 full-year figure at -$43.8 million, up 27.25% from the prior year.
• Net Cash Flow was -$5.3 million for Q2 2026 at Twist Bioscience, up from -$26.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $216.0 million in Q1 2022 and troughed at -$61.4 million in Q4 2022.
• A 5-year average of -$4.1 million and a median of -$12.1 million in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 327.75% in 2022 and slumped 1324.52% in 2024, its largest moves.
• Over 5 years, Net Cash Flow stood at -$61.4 million in 2022, then surged by 66.99% to -$20.3 million in 2023, then jumped by 75.25% to -$5.0 million in 2024, then plunged by 586.24% to -$34.4 million in 2025, then soared by 84.63% to -$5.3 million in 2026.
• The last three Net Cash Flow figures came in at -$5.3 million (Q2 2026), -$26.1 million (Q1 2026), and -$34.4 million (Q4 2025), per Business Quant data.